The retroviral life cycle and safety considerations for retroviral mediated gene therapy (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


The retroviral life cycle and safety considerations for retroviral mediated gene therapy (Meeting abstract).

Gene Therapy for Neoplastic Diseases. June 26-29, 1993, Washington, DC, A7, 1993.. Unique Identifier : AIDSLINE ICDB/94698154
Boris-Lawrie K; Temin HM; McArdle Lab. for Cancer Res., Univ. of Wisconsin, Madison, WI

Abstract: The life cycle of retroviruses makes them uniquely suited as vectors for gene therapy. Safety is the primary consideration when designing retroviral vectors and helper cells. Retroviral vectors used for gene therapy are based on simpler retroviruses (SRV), which do not cause disease in humans and ungulates. Retroviral disease in these species is caused by more complex retroviruses (MCRVs). We have converted the genome structure of an MCRV, bovine leukemia virus (BLV), to resemble that of a SRV. These simpler BLV vectors can replicate, and animal studies are underway to determine if the simple BLV is an effective vaccine against wild-type BLV infection. Preliminary experiments indicate that a simpler HIV-1 vector can also replicate. SRV versions of MCRVs may be useful as preventive vaccines against disease caused by MCRVs.
Keywords: *Gene Therapy Genetic Vectors Human HIV-1/GENETICS Retroviridae/*GENETICS/PHYSIOLOGY ABSTRACT

KWDgenetherapygeneticvectorshumanhiv-1/geneticsretroviridae/KWDgenetics/physiologyabstract
940930
M9491061

Copyright © 1994 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .